Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-000888-27
    Sponsor's Protocol Code Number:GTR001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2011-000888-27
    A.3Full title of the trial
    Multi-centre, randomized, double-blind, placebo-controlled, parallelgroup, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects
    Studio di equivalenza multicentrico, randomizzato, in doppio cieco, controllato con placebo, a gruppi paralleli, della durata di 9 mesi, per confrontare l'efficacia, la sicurezza e la tollerabilita' di GTR (Synthon BV) rispetto a Copaxone (Teva) in soggetti con sclerosi multipla recidivante remittente, cui seguira' un trattamento con GTR della durata di 15 mesi, in aperto, per valutare gli effetti del trattamento a lungo termine con tale farmaco.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.
    Uno studio clinico per confrontare l’efficacia, la sicurezza e la tollerabilita' di due farmaci modificanti la Sclerosi Multipla (GTR e Copaxone) in soggetti con sclerosi multipla recidivante remittente, cui seguira' un trattamento con GTR della durata di 15 mesi, in aperto, per valutare l’efficacia e la sicurezza del trattamento a lungo termine con tale farmaco.
    A.3.2Name or abbreviated title of the trial where available
    GATE
    GATE
    A.4.1Sponsor's protocol code numberGTR001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSYNTHON BV
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSynthon BV
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPSI Pharma Support Romania SRL
    B.5.2Functional name of contact pointRegulatory Affairs
    B.5.3 Address:
    B.5.3.1Street Address2 Gara Dealul Spirii
    B.5.3.2Town/ cityBucharest
    B.5.3.3Post code050689
    B.5.3.4CountryRomania
    B.5.4Telephone number0040214024300
    B.5.5Fax number0040214024310
    B.5.6E-mailRAEurope@psi-cro.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameglatiramer acetate
    D.3.2Product code GTR
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGLATIRAMER ACETATE
    D.3.9.1CAS number 147245-92-9
    D.3.9.2Current sponsor codeGTR
    D.3.9.3Other descriptive nameGTR.ace
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Copaxone
    D.2.1.1.2Name of the Marketing Authorisation holderTeva Pharmaceuticals Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGLATIRAMER ACETATE
    D.3.9.1CAS number 147245-92-9
    D.3.9.3Other descriptive nameglatiramer acetate
    D.3.9.4EV Substance CodeSUB13971MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing remitting multiple sclerosis
    Sclerosi Multipla Recidivante Remittente
    E.1.1.1Medical condition in easily understood language
    Multiple sclerosis is an inflammatory disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged.
    La Sclerosi Multipla è un malattia infiammatoria in cui le guaine mieliniche adipose intorno gli assoni del cervello e del midollo spinale sono danneggiate.
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level SOC
    E.1.2Classification code 10029205
    E.1.2Term Nervous system disorders
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this trial is: • to demonstrate that the efficacy of Synthon‟s glatiramer acetate (GTR) is equivalent to Copaxone (TEVA) in subjects with relapsing remitting multiple sclerosis (RRMS) as measured by the number of gadolinium-enhancing lesions on T1-weighted MRIs during the months 7-9. To demonstrate that the efficacy of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone (TEVA) in subjects with relapsing remitting multiple sclerosis (RRMS) as measured by the number of gadoliniumenhancing lesions on T1-weighted MRIs during the months 7-9.
    Per dimostrare che l’efficacia del glatiramer acetato (GTR) di Synthon è equivalente a Copaxone (TEVA) in soggetti con Sclerosi Multipla Recidivante Remittente (SMRR) come misurato dal numero di lesioni T1 pesate captanti il gadolinio durante i mesi 7-9.
    E.2.2Secondary objectives of the trial
    Blinded phase: • to compare the efficacy of GTR to Copaxone based on MRI parameters • to compare the efficacy of GTR to Copaxone based on the annualized relapse rate; • to compare the efficacy of GTR to Copaxone based on the changes in EDSS; • to compare the efficacy of GTR to Copaxone based on the percentage subjects free from disease activity at month 9; • to compare the percentage of subjects with anti-glatiramer antibodies after GTR and Copaxone treatment. Open-label phase: • to evaluate efficacy, safety and tolerability of long-term (2-years) GTR treatment; • to evaluate efficacy, safety and tolerability of switching to GTR treatment after previous Copaxone use.
    Fase in cieco:
    • confrontare l’efficacia di GTR rispetto a Copaxone sulla base dei parametri di Risonanza Magnetica
    • confrontare l’efficacia di GTR rispetto a Copaxone sulla base del tasso annualizzato di recidiva
    • confrontare l’efficacia di GTR rispetto a Copaxone sulla base delle variazioni all'EDSS;
    • confrontare l’efficacia di GTR rispetto a Copaxone sulla base della percentuale di soggetti con assenza di attività della malattia al mese 9;
    • confrontare la percentuale di soggetti con anticorpi anti-glatiramer dopo trattamento con GTR e Copaxone.
    Fase in aperto:
    • valutare l’efficacia, la sicurezza e la tollerabilità del trattamento con GTR a lungo termine (2 anni)
    • valutare l’efficacia, la sicurezza e la tollerabilità del passaggio al trattamento con GTR dopo avere in precedenza utilizzato Copaxone
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Willing and able to sign written Informed Consent; 2. Female and male subjects aged 18-55 years inclusive at the time of Informed Consent signing; 3. Diagnosis of RRMS according to the revised McDonald criteria 4. XML File Identifier: yNieNjgZsU9hdR2vawv4zncMnY8= Page 15/30 Expanded Disability Status Scale (EDSS) score of 0.0 up to and including 5.5; 5. Neurologically stable with no evidence of relapse within 30 days prior to randomization; 6. Experienced at least 1 relapse in the year before first screening assessment; 7. At least 1 T1-weighted Gadolinium enhancing (T1-GdE) lesion on routine brain MRI taken within 3 months of starting screening or on screening brain MRI (as confirmed by central imaging laboratory); 8. Having a routine brain MRI showing maximally 15 T1-GdE lesions if scan is taken without subject receiving immuno-modulatory treatment, or a routine brain MRI showing maximally 5 T1-GdE lesions when taken while on immune-modulatory treatment, or a screening MRI showing maximally 15 T1-GdE lesions; 9. Must decline initiation or continuation of treatment with other available disease-modifying drugs for MS, for whatever reason, after having been informed about their respective benefits and possible adverse events by the investigator; 10. Female subjects of childbearing potential must agree to practice appropriate contraceptive methods as assessed by the investigator.
    1. volontà e capacità di firmare il consenso informato scritto; 2. soggetti di sesso maschile e femminile di età compresa tra i 18 e i 55 anni compiuti al momento della firma del consenso informato; 3. diagnosi di SMRR secondo i nuovi criteri diagnostici di McDonald (Revisioni 2010) [1]; 4. punteggio ottenuto alla EDSS (Expanded Disability Status Scale) da 0,0 fino a 5,5 compreso; 5. pazienti neurologicamente stabili senza segni di recidiva nei 30 giorni precedenti la randomizzazione; 6. comparsa di almeno 1 recidiva nell’anno precedente la prima valutazione di screening; 7. almeno 1 lesione captante il gadolinio nelle immagini pesate in T1 (T1-GdE) alla RM cerebrale di routine eseguita entro 3 mesi dall'inizio dello screening, oppure alla RM cerebrale di screening (confermata dal laboratorio centrale di diagnostica per immagini) 8. RM cerebrale di routine che riveli la presenza massima di 15 lesioni T1-GdE nel periodo in cui il soggetto non riceveva alcun trattamento con immunomodulatori, oppure RM cerebrale di routine che riveli la presenza massima di 5 lesioni T1-GdE nel periodo in cui il soggetto riceveva il trattamento con immunomodulatori, oppure RM di screening che riveli la presenza massima di 15 lesioni T1-GdE; 9. rifiuto di iniziare o continuare il trattamento con tutti gli altri farmaci modificanti la malattia disponibili per la SM, per qualunque ragione, dopo essere stati informati dallo sperimentatore sui rispettivi benefici e sui possibili eventi avversi; 10. i soggetti di sesso femminile in età fertile devono accettare di adottare idonei metodi contraccettivi valutati dallo sperimentatore.
    E.4Principal exclusion criteria
    1. Any life-threatening, medically unstable or otherwise clinically significant condition or findings other than MS, in particular neoplastic disease, seizure disorders, or psychiatric disease; 2. Any clinically significant deviation from reference ranges in laboratory tests; 3. Positive laboratory test results for human immunodeficiency virus (HIV), HBsAg or HCV at screening; 4. Any significant deviation from reference ranges for hepatic function as defined by either AST (SGOT), ALT (SGPT), GGT, or AP elevated 3-fold or higher beyond the upper limit of the reference range or total bilirubin elevated 2-fold or higher beyond the upper limit of the reference range (in case of Gilbert's Syndrome, a joint documented decision will be made between the investigator and the Medical Officer); 5. Positive urine drug screen or history of substance abuse within the year before screening (any use of illicit or prescription drugs or alcohol constituting an abuse pattern in the opinion of the investigator); 6. Having been treated with or having received a. at any time: • glatiramer acetate, cladribine, rituximab, cyclophosphamide, alemtuzumab, or other immunosuppressive treatments with effects potentially lasting for more than 6 months; • total lymphoid irradiation or bone marrow transplantation; b. within one year before screening: • mitoxantrone, but subject cannot be enrolled when mitoxantrone was taken at a cumulative lifetime dosing above 100 mg/m2; c. within 6 months before screening: • fingolimod, immunoglobulins and/or monoclonal antibodies (including natalizumab), leflunomide, or putative MS treatments; • chronic oral or injected corticosteroids or injected ACTH (more than 30 consecutive days); d. within 3 months before screening: • azathioprine, methotrexate; • plasma exchange; • any other experimental intervention, in particular experimental drugs; e. within 1 month before screening: • Interferon-β 1a or 1b; • short-term oral or injectable corticosteroids for treatment of a relapse; • short-term ACTH; 7. Having, in the opinion of the investigator, consecutively failed on efficacy grounds two full and adequate courses of accepted treatment modalities (normally at least one year of treatment for each); 8. Pregnancy or breastfeeding; 9. Known hypersensitivity to gadolinium-containing products, glatiramer acetate or mannitol; 10. Having an estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2; 11. Inability to undergo (repeat) MRI investigations as judged by the investigator, e.g., due to claustrophobia, metal implants or fragments, tattoos or permanent make-up; 12. Any reason why, in the investigator's opinion, the subject should not participate.
    1. Qualunque malattia grave, clinicamente instabile o clinicamente rilevante o reperti diversi dalla SM, in particolare malattie neoplastiche, epilessia o malattie psichiatriche (in caso di dubbio si dovrà consultare l'ufficiale sanitario responsabile, che insieme allo sperimentatore dovrà prendere una decisione congiunta documentata); 2. qualsiasi deviazione clinicamente significativa dagli intervalli di riferimento nei test di laboratorio (in caso di dubbio si dovrà consultare l'ufficiale sanitario responsabile, che insieme allo sperimentatore dovrà prendere una decisione congiunta documentata); 3. risultati positivi dei test di laboratorio per virus dell’immunodeficienza umana (HIV), HBsAG o HCV allo screening; 4. qualsiasi deviazione significativa dagli intervalli di riferimento relativi alla funzionalità epatica misurata in base ai valori di AST (SGOT), ALT (SGPT), GGT o AP, 3 o più volte al di sopra del limite superiore dell'intervallo di riferimento, o di bilirubina totale, 2 o più volte al di sopra del limite superiore dell'intervallo di riferimento (qualora ai soggetti venga diagnosticata la sindrome di Gilbert, occorrerà contattare l'ufficiale sanitario, che insieme allo sperimentatore dovrà prendere una decisione congiunta documentata); 5. positività al test delle urine, o precedenti di abuso di sostanze nell’anno precedente lo screening (qualunque uso di farmaci da prescrizione o illegali o di alcol costituisce, secondo lo sperimentatore, una situazione di abuso); 6. essere stati trattati con, o aver assunto a. in qualsiasi momento: • glatiramer acetato, cladribina, rituximab, ciclofosfamide, alemtuzumab o altri trattamenti immunosoppressivi con effetti che possono durare per oltre 6 mesi; • irradiazione linfoide totale o trapianto di midollo osseo; b. nell’anno precedente lo screening; • mitoxantrone, ma il soggetto non può essere arruolato se il mitoxantrone è stato assunto a un dosaggio cumulativo nel corso della vita superiore a 100 mg/m2; c. nei 6 mesi precedenti lo screening: • fingolimod, immunoglobuline e/o anticorpi monoclonali (compreso natalizumab), leflunomide o presunti trattamenti per la SM; • terapia corticosteroidea cronica per via orale o iniettiva, o ACTH per via iniettiva (per oltre 30 giorni consecutivi); d. nei 3 mesi precedenti lo screening: • azatioprina, metotrexato; • scambio plasmatico; • qualsiasi altro intervento sperimentale, soprattutto farmaci sperimentali; e. nel mese precedente lo screening: • Interferone-β 1a o 1b; • terapia corticosteroidea a breve termine per via orale o iniettiva per il trattamento di una recidiva; • ACTH a breve termine; 7. non aver ottenuto, secondo lo sperimentatore, nessun vantaggio in termini di efficacia per due volte consecutive in due cicli di trattamento completi e idonei eseguiti con modalità comprovate (di durata normalmente pari a un anno ciascuno); 8. gravidanza o allattamento; 9. ipersensibilità nota a prodotti contenenti gadolinio, glatiramer acetato o mannitolo; 10. velocità di filtrazione glomerulare stimata (eGFR) &lt;50 mL/min/1,73m2; 11. impossibilità, secondo lo sperimentatore, di sottoporsi a RM (o ripeterla), a causa ad esempio di claustrofobia, protesi o frammenti metallici, tatuaggi o make-up permanente; 12. qualsiasi motivo giudicato sufficiente, secondo lo sperimentatore, a escludere il soggetto.
    E.5 End points
    E.5.1Primary end point(s)
    The number of Gadolinium enhancing lesions.
    Il numero di lesioni captanti il Gadolinio
    E.5.1.1Timepoint(s) of evaluation of this end point
    the months 7-9 after start of treatment
    I mesi 7-9 dopo l’inizio del trattamento
    E.5.2Secondary end point(s)
    • MRI parameters; • Annualized relapse rate; • EDSS change from baseline; • Percentage subjects ''Free from disease activity''; • Percentage of subjects with anti-glatiramer antibodies formation.
    • Parametri di RM
    • Tasso annuale di recidiva
    • Variazioni all'EDSS dal basale
    • Percentuale di soggetti con assenza di attività della malattia
    • Percentuale di soggetti con la formazione di anticorpi anti-glatiramer
    E.5.2.1Timepoint(s) of evaluation of this end point
    as per trial objectives and trial flowchart, page 7 and 8 of protocol
    Per gli obiettivi e il diagramma di flusso dello studio vedere le pagine 7 e 9 del protocollo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Seguito da un trattamento in aperto della durata di 15 mesi
    followed by open-label 15 month GTR treatment
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA59
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Croatia
    Russian Federation
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 750
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    MS suffering volunteers for MRI dry run procedure
    MS suffering volunteers for MRI dry run procedure
    F.4 Planned number of subjects to be included
    F.4.1In the member state55
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 344
    F.4.2.2In the whole clinical trial 750
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    To ensure long-term access for subjects a named-patient program might be installed through which subjects can continue to receive GTR, until the time the product is approved and reimbursed on the local market.
    Per assicurare un accesso a lungo termine ai soggetti, un programma nome-paziente potrebbe essere istituito per quei pazienti che possono continuare a ricevere GTR, finché il prodotto non verrà approvato e rimborsato nel mercato locale.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-10-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-07-21
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 05:44:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA